Dual effects of auranofin on prostaglandin E2 production by rat peritoneal macrophages

European Journal of Pharmacology

Volumn 325, Issue 2-3, 1997, Pages 221-227

  Yamashita, Masamichi ^a   Niki, Hisae ^a   Yamada, Masateru ^a   Watanabe Kobayashi, Masako ^a   Mue, Suetsugu ^b   Ohuchi, Kazuo ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b Japan   (Japan)

Author keywords

12 O Tetradecanoylphorbol 13 acetate; A23187; Auranofin; Cyclooxygenase 1; Cyclooxygenase 2; Macrophage; Prostaglandin E2; Thapsigargin

Indexed keywords

ARACHIDONIC ACID; AURANOFIN; CALCIMYCIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; PROSTAGLANDIN E2; THAPSIGARGIN;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; IMMUNOBLOTTING; MALE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; RAT;

ANIMALS; ANTIRHEUMATIC AGENTS; ARACHIDONIC ACID; AURANOFIN; CALCIMYCIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DINOPROSTONE; IONOPHORES; ISOENZYMES; MACROPHAGES, PERITONEAL; MALE; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RATS; RATS, SPRAGUE-DAWLEY; TETRADECANOYLPHORBOL ACETATE; THAPSIGARGIN;

EID: 0030969469     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)00118-0     Document Type: Article

References (32)

1. 2 in mouse macrophages. J. Leukocyte Biol. 54, 329-335.
2. Bondeson, J., Sundler, R., 1995. Auranofin inhibits the induction of interleukin 1β and tumor necrosis factor α mRNA in macrophages. Biochem. Pharmacol. 50, 1753-1759.
3. Carette, S., Calin, A., McCafferty, J.P., Wallin, B.A., 1989. A double-blind placebo-controlled study of auranofin in patients with psoriatic arthritis. Arthritis Rheum. 32, 158-165.
4. Crofford, L.J., Wilder, R.L., Ristimaki, A.P., Sano, H., Remmers, E.F., Epps, H.R., Hla, T., 1994. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1β, phorbol ester, and corticosteroids. J. Clin. Invest. 93, 1095-1101.
5. Davis, P., Johnston, C., Miller, C.L., Wong, K., 1983. Effects of gold compounds on the function of phagocytic cells. II. Inhibition of superoxide radical generation by tripeptide-activated polymorphonuclear leukocytes. Arthritis Rheum. 26, 82-86.
6. Degitz, K., Li, L.J., Caughman, S.W., 1991. Cloning and characterization of the 5′-transcriptional regulatory region of the human intercellular adhesion molecule 1 gene. J. Biol. Chem. 266, 14024-14030.
7. DiMartino, M.J., Waltz, D.T., 1977. Inhibition of lysosomal enzyme release from rat leukocytes by auranofin. Inflammation 2, 131-142.
8. Elmgreen, J., Ahnfelt-Ronne, I., Nielsen, O.H., 1989. Inhibition of human neutrophils by auranofin: chemotaxis and metabolism of arachidonate via the 5-lipoxygenase pathway. Ann. Rheum. Dis. 48, 134-138.
9. Finkelstein, A.E., Roisman, F.R., Waltz, D.T., 1977. Effect of auranofin, a new antiarthritic agent, on immune complex-induced release of lysosomal enzymes from human leukocytes. Inflammation 2, 143-150.
10. Gottlieb, N.L., 1982. Comparative pharmacokinetics of parenteral and oral gold compounds. J. Rheumatol. 9 (Suppl. 8), 99-109.
11. Hafstrom, I., Uden, A.M., Palmblad, J., 1983. Modulation of neutrophil functions by auranofin. Studies on effects in vitro and in rheumatoid arthritis patients. Scand. J. Rheumatol. 12, 97-105.
12. 4 formation by human polymorphonuclear leukocytes. Biochem. Pharmacol. 36, 1475-1481.
13. Lee, S.H., Soyoola, E., Chanmugam, P., Hart, S., Sun, W., Zhong, H., Liou, S., Simmons, D., Hwang, D., 1992. Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. J. Biol. Chem. 267, 25934-25938.
14. Lewis, A.J., Carlson, R.P., Chang, J., Delustro, F., 1984. Effect of gold salts, D-penicillamine and benoxaprofen on type II collagen-induced arthritis in rats. Agents Actions 14, 707-714.
15. Neish, A.S., Williams, A.J., Palmer, H.J., Whitley, M.Z., Collins, T., 1992. Functional analysis of the human vascular cell adhesion molecule 1 promoter. J. Exp. Med. 176, 1583-1593.
16. Nishizuka, Y., 1992. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 258, 607-614.
17. 2 production by activated peritoneal macrophages from rats. Prostaglandins Med. 7, 457-463.
18. 2 production by 12-O-tetradecanoylphorbol 13-acetate (TPA)-type and non-TPA-type tumor promoters in macrophages and its inhibition by cycloheximide. Biochim. Biophys. Acta 834, 42-47.
19. Ohuchi, K., Sugawara, T., Watanabe, M., Hirasawa, N., Tsurufuji, S., Fujiki, H., Christensen, S.B., Sugimura, T., 1988. Analysis of the stimulative effect of thapsigargin, a non-TPA-type tumour promoter, on arachidonic acid metabolism in rat peritoneal macrophages. Br. J. Pharmacol. 94, 917-923.
20. 2 production by polymorphonuclear leukocytes. J. Rheumatol. 13, 47-51.
21. Peters-Golden, M., Shelly, C., 1988. The oral gold compound auranofin triggers arachidonate release and cyclooxygenase metabolism in the alveolar macrophage. Prostaglandins 36, 773-786.
22. Peters-Golden, M., Shelly, C., 1989. Inhibition of alveolar macrophage 5-lipoxygenase metabolism by auranofin. Biochem. Pharmacol. 38, 1589-1595.
23. Sano, H., Hla, T., Maier, J.A.M., Crofford, L.J., Case, J.P., Maciag, T., Wilder, R.L., 1992. In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis. J. Clin. Invest. 89, 97-108.
24. Sato, H., Yamaguchi, M., Shibasaki, T., Ishii, T., Bannai, S., 1995. Induction of stress proteins in mouse peritoneal macrophages by the anti-rheumatic agents gold sodium thiomalate and auranofin. Biochem. Pharmacol. 49, 1453-1457.
25. Scheinberg, M.A., Santos, L.M.B., Finkelstein, A.E., 1982. The effect of auranofin and sodium aurothiomalate on peripheral blood monocytes. J. Rheumatol. 9, 366-369.
26. Sirois, J., Richards, J.S., 1993. Transcriptional regulation of the rat prostaglandin endoperoxide synthase 2 gene in granulosa cells. Evidence for the role of a cis-acting C/EBP β promoter element. J. Biol. Chem. 268, 21931-21938.
27. Thastrup, O., Foder, B., Scharff, O., 1987. The calcium mobilizing and tumor promoting agent, thapsigargin elevates the platelet cytoplasmic free calcium concentration to a higher steady state level. A possible mechanism of action for the tumor promotion. Biochem. Biophys. Res. Commun. 142, 654-660.
28. Wang, C., Smith, R.L., 1975. Lowry determination of protein in the presence of Triton X-100. Anal. Biochem. 63, 414-417.
29. Ward, J.R., Williams, H.J., Egger, M.J., Reading, J.C., Boyce, E., Altz-Smith, M., Samuelson Jr., C.O., Willkens, R.F., Solsky, M.A., Hayes, S.P., Blocka, K.L., Weinstein, A., Meenan, R.F., Guttadauria, M., Kaplan, S.B., Klippel, J., 1983. Comparison of auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum. 26, 1303-1315.
30. Watanabe, M., Yamada, M., Mue, S., Ohuchi, K., 1995, Enhancement by cyclo-oxygenase inhibitors of platelet-activating factor production in thapsigargin-stimulated macrophages. Br. J. Pharmacol. 116, 2141-2147.
31. Wenger, M.E., Alexander, S., Bland, J.H., Blechman, W.J., 1983. Auranofin versus placebo in the treatment of rheumatoid arthritis. Am. J. Med. 75, 123-127.
32. Yang, J.P., Merin, J.P., Nakano, T., Kato, T., Kitade, Y., Okamoto, T., 1995. Inhibition of the DNA-binding activity of NF-KB by gold compounds in vitro. FEBS Lett. 361, 89-96.